Supernus Pharmaceuticals
SUPN
#5126
Rank
โ‚ฌ1.57 B
Marketcap
27,07ย โ‚ฌ
Share price
1.78%
Change (1 day)
-30.42%
Change (1 year)

EPS for Supernus Pharmaceuticals (SUPN)

EPS in 2026 (TTM): -0,66ย โ‚ฌ

According to Supernus Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -0,69ย โ‚ฌ. In 2025 the company made an earnings per share (EPS) of -0,62ย โ‚ฌ a decrease over its 2024 EPS that were of 1,22ย โ‚ฌ.

EPS history for Supernus Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)-0,66ย โ‚ฌ6.77%
2025-0,62ย โ‚ฌ-150.75%
20241,22ย โ‚ฌ
20221,03ย โ‚ฌ10.78%
20210,93ย โ‚ฌ-57.68%
20202,20ย โ‚ฌ12.09%
20191,96ย โ‚ฌ0.47%
20181,95ย โ‚ฌ89.38%
20171,03ย โ‚ฌ-38.59%
20161,68ย โ‚ฌ534.48%
20150,26ย โ‚ฌ-211.54%
2014-0,24ย โ‚ฌ-91.1%
2013-2,66ย โ‚ฌ39.46%
2012-1,91ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
6,08ย โ‚ฌ-978.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
2,46ย โ‚ฌ-455.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
28,14ย โ‚ฌ-4,164.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
4,12ย โ‚ฌ-694.74%๐Ÿ‡บ๐Ÿ‡ธ USA
United Therapeutics
UTHR
26,06ย โ‚ฌ-3,864.47%๐Ÿ‡บ๐Ÿ‡ธ USA